MedTrace Logo

Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage

NCT07401524 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-05-08

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if the drug carbetocin works better than standard care to prevent heavy bleeding after childbirth in people carrying twin pregnancies. Heavy bleeding after delivery, also called postpartum hemorrhage, is more common after twin births and can lead to anemia, blood transfusions, and other serious health problems.

In this study, bleeding will be evaluated by measuring how much blood hemoglobin levels drop from before delivery to the day after delivery.

The main questions this study aims to answer are:

* Does giving carbetocin after delivery lower blood loss compared with standard oxytocin treatment?
* Is carbetocin safe and practical to use in twin deliveries?

Researchers will compare carbetocin to standard oxytocin treatment to see which approach better prevents bleeding after twin vaginal or cesarean delivery.

Participants will:

* Be randomly assigned to receive either carbetocin or standard oxytocin after the second twin is delivered
* Have blood tests before delivery and on the day after delivery
* Be followed during their hospital stay and for up to six weeks after delivery for safety outcomes

Conditions

  • Postpartum Hemorrhage
  • Twin Pregnancy

Interventions

DRUG

Carbetocin

Carbetocin will be administered as a single intravenous dose immediately following delivery of the second twin, according to institutional protocol, for the prevention of postpartum hemorrhage.

DRUG

Oxytocin

Oxytocin will be administered intravenously according to standard institutional practice, for the prevention of postpartum hemorrhage.

Sponsors & Collaborators

  • Sheba Medical Center

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-05
Primary Completion
2028-03-01
Completion
2028-12-01

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07401524 on ClinicalTrials.gov